Global Brain Tumor Therapeutics Market

Brain Tumor Therapeutics Comprehensive Study by Type (MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing, EEG), Treatment Type (Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, Immunotherapy, Others), Tumor Type (Primary Brain Tumor, Secondary Brain Tumor) Players and Region - Global Market Outlook to 2029

Brain Tumor Therapeutics Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Brain Tumor Therapeutics
Brain tumor therapeutics helps cure abnormal growth of cells inside the brain. Owing to rising cases of brain disorder related death, companies are focusing on developing remedial methods. With over 769,970 estimated cases in United States alone till 2019, brain tumor is causing significant harm to individuals' health. Recently, various therapeutics techniques have been developed yet, a lot has to be done.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)


Brain Tumor Therapeutics is a fragmented market due to the presence of various players. The players are focusing on strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Brain Tumor Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

NOVARTIS [Switzerland], F. HOFFMAN LA-ROCHE LTD. [Switzerland], MERCK & CO. Inc. [United States], IMMUNOCELLULAR THERAPEUTICS LTD. [United States], NOVOCURE [United States], DEL MAR PHARMACEUTICALS INC. [Canada] and MOLECULIN BIOTEC. [United States] are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Siemens Healthineers [Germany], Hitachi Healthcare [United States], Philips Healthcare [Netherlands], Canon Medical Systems Corporation [Japan] and Shimadzu Corp [Japan].

Segmentation Overview
AMA Research has segmented the market of Global Brain Tumor Therapeutics market by Type (MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing and EEG) and Region.



On the basis of geography, the market of Brain Tumor Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment Type, the sub-segment i.e. Surgery will boost the Brain Tumor Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Tumor Type, the sub-segment i.e. Primary Brain Tumor will boost the Brain Tumor Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emerging Applications of Gene Therapy in Regenerative Medicine Technological Advances in Regenerative Medicine (Stem Cell, Tissue Engineering, and Nanotechnology)

Market Growth Drivers:
Increasing Adoption of Stem Cell Technology and Growing Prevalence of Chronic Diseases

Restraints:
High Cost of Treatment and Less Awareness and Regulatory and Ethical Issues Pertaining Stem Cell, Tissues Engineering and Regenerative Medicine

Opportunities:
High Investment & Funding To Support Development of RM

Market Leaders and their expansionary development strategies
In December 2023, GT Medical Technologies, Inc. ("GT Medical Technologies"), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, announced it has agreed to acquire substantially all of the radioactive Cesium-131 seed assets and related business infrastructure from Isoray Medical, which is a subsidiary of Perspective Therapeutics, Inc. ("Isoray"). GT Medical Technologies' GammaTile Therapy is FDA-cleared to treat patients with operable brain tumors to eliminate residual tumor cells.
In March 2023, New research has shown that the blood vessels that feed aggressive brain tumours have receptors that could allow a new type of drug-containing nanoparticle to be used to starve the tumours of the energy they use to grow and spread, and also cause other disruptions to their adapted existence, even killing themselves.


Key Target Audience
Healthcare Sectors, Potential Investors, Research Institutes, Government Agencies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • MRI
  • CT Scan
  • Tissue Sampling
  • PET-CT Scan
  • Cerebral Arteriogram
  • Lumbar Puncture
  • Molecular Testing
  • EEG
By Treatment Type
  • Surgery
  • Radiation Therapy
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Others

By Tumor Type
  • Primary Brain Tumor
  • Secondary Brain Tumor

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Adoption of Stem Cell Technology
      • 3.2.2. Growing Prevalence of Chronic Diseases
    • 3.3. Market Trends
      • 3.3.1. Emerging Applications of Gene Therapy in Regenerative Medicine Technological Advances in Regenerative Medicine (Stem Cell, Tissue Engineering, and Nanotechnology)
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Brain Tumor Therapeutics, by Type, Treatment Type, Tumor Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Brain Tumor Therapeutics (Value)
      • 5.2.1. Global Brain Tumor Therapeutics by: Type (Value)
        • 5.2.1.1. MRI
        • 5.2.1.2. CT Scan
        • 5.2.1.3. Tissue Sampling
        • 5.2.1.4. PET-CT Scan
        • 5.2.1.5. Cerebral Arteriogram
        • 5.2.1.6. Lumbar Puncture
        • 5.2.1.7. Molecular Testing
        • 5.2.1.8. EEG
      • 5.2.2. Global Brain Tumor Therapeutics by: Treatment Type (Value)
        • 5.2.2.1. Surgery
        • 5.2.2.2. Radiation Therapy
        • 5.2.2.3. Targeted Therapy
        • 5.2.2.4. Chemotherapy
        • 5.2.2.5. Immunotherapy
        • 5.2.2.6. Others
      • 5.2.3. Global Brain Tumor Therapeutics by: Tumor Type (Value)
        • 5.2.3.1. Primary Brain Tumor
        • 5.2.3.2. Secondary Brain Tumor
      • 5.2.4. Global Brain Tumor Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Brain Tumor Therapeutics (Price)
      • 5.3.1. Global Brain Tumor Therapeutics by: Type (Price)
  • 6. Brain Tumor Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. NOVARTIS [Switzerland]
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. HOFFMAN LA-ROCHE LTD. [Switzerland]
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. MERCK & CO. Inc. [United States]
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. IMMUNOCELLULAR THERAPEUTICS LTD. [United States]
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. NOVOCURE [United States]
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. DEL MAR PHARMACEUTICALS INC. [Canada]
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MOLECULIN BIOTEC. [United States]
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Brain Tumor Therapeutics Sale, by Type, Treatment Type, Tumor Type and Region (value and price ) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Brain Tumor Therapeutics (Value)
      • 7.2.1. Global Brain Tumor Therapeutics by: Type (Value)
        • 7.2.1.1. MRI
        • 7.2.1.2. CT Scan
        • 7.2.1.3. Tissue Sampling
        • 7.2.1.4. PET-CT Scan
        • 7.2.1.5. Cerebral Arteriogram
        • 7.2.1.6. Lumbar Puncture
        • 7.2.1.7. Molecular Testing
        • 7.2.1.8. EEG
      • 7.2.2. Global Brain Tumor Therapeutics by: Treatment Type (Value)
        • 7.2.2.1. Surgery
        • 7.2.2.2. Radiation Therapy
        • 7.2.2.3. Targeted Therapy
        • 7.2.2.4. Chemotherapy
        • 7.2.2.5. Immunotherapy
        • 7.2.2.6. Others
      • 7.2.3. Global Brain Tumor Therapeutics by: Tumor Type (Value)
        • 7.2.3.1. Primary Brain Tumor
        • 7.2.3.2. Secondary Brain Tumor
      • 7.2.4. Global Brain Tumor Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Brain Tumor Therapeutics (Price)
      • 7.3.1. Global Brain Tumor Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Brain Tumor Therapeutics: by Type(USD Million)
  • Table 2. Brain Tumor Therapeutics MRI , by Region USD Million (2018-2023)
  • Table 3. Brain Tumor Therapeutics CT Scan , by Region USD Million (2018-2023)
  • Table 4. Brain Tumor Therapeutics Tissue Sampling , by Region USD Million (2018-2023)
  • Table 5. Brain Tumor Therapeutics PET-CT Scan , by Region USD Million (2018-2023)
  • Table 6. Brain Tumor Therapeutics Cerebral Arteriogram , by Region USD Million (2018-2023)
  • Table 7. Brain Tumor Therapeutics Lumbar Puncture , by Region USD Million (2018-2023)
  • Table 8. Brain Tumor Therapeutics Molecular Testing , by Region USD Million (2018-2023)
  • Table 9. Brain Tumor Therapeutics EEG , by Region USD Million (2018-2023)
  • Table 10. Brain Tumor Therapeutics: by Treatment Type(USD Million)
  • Table 11. Brain Tumor Therapeutics Surgery , by Region USD Million (2018-2023)
  • Table 12. Brain Tumor Therapeutics Radiation Therapy , by Region USD Million (2018-2023)
  • Table 13. Brain Tumor Therapeutics Targeted Therapy , by Region USD Million (2018-2023)
  • Table 14. Brain Tumor Therapeutics Chemotherapy , by Region USD Million (2018-2023)
  • Table 15. Brain Tumor Therapeutics Immunotherapy , by Region USD Million (2018-2023)
  • Table 16. Brain Tumor Therapeutics Others , by Region USD Million (2018-2023)
  • Table 17. Brain Tumor Therapeutics: by Tumor Type(USD Million)
  • Table 18. Brain Tumor Therapeutics Primary Brain Tumor , by Region USD Million (2018-2023)
  • Table 19. Brain Tumor Therapeutics Secondary Brain Tumor , by Region USD Million (2018-2023)
  • Table 20. South America Brain Tumor Therapeutics, by Country USD Million (2018-2023)
  • Table 21. South America Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 22. South America Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 23. South America Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 24. Brazil Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 25. Brazil Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 26. Brazil Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 27. Argentina Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 28. Argentina Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 29. Argentina Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 30. Rest of South America Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 32. Rest of South America Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 33. Asia Pacific Brain Tumor Therapeutics, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 35. Asia Pacific Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 36. Asia Pacific Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 37. China Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 38. China Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 39. China Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 40. Japan Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 41. Japan Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 42. Japan Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 43. India Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 44. India Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 45. India Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 46. South Korea Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 47. South Korea Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 48. South Korea Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 49. Taiwan Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 50. Taiwan Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 51. Taiwan Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 52. Australia Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 53. Australia Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 54. Australia Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 57. Rest of Asia-Pacific Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 58. Europe Brain Tumor Therapeutics, by Country USD Million (2018-2023)
  • Table 59. Europe Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 60. Europe Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 61. Europe Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 62. Germany Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 63. Germany Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 64. Germany Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 65. France Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 66. France Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 67. France Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 68. Italy Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 69. Italy Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 70. Italy Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 71. United Kingdom Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 72. United Kingdom Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 73. United Kingdom Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 74. Netherlands Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 75. Netherlands Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 76. Netherlands Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 77. Rest of Europe Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 78. Rest of Europe Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 79. Rest of Europe Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 80. MEA Brain Tumor Therapeutics, by Country USD Million (2018-2023)
  • Table 81. MEA Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 82. MEA Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 83. MEA Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 84. Middle East Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 85. Middle East Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 86. Middle East Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 87. Africa Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 88. Africa Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 89. Africa Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 90. North America Brain Tumor Therapeutics, by Country USD Million (2018-2023)
  • Table 91. North America Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 92. North America Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 93. North America Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 94. United States Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 95. United States Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 96. United States Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 97. Canada Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 98. Canada Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 99. Canada Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 100. Mexico Brain Tumor Therapeutics, by Type USD Million (2018-2023)
  • Table 101. Mexico Brain Tumor Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 102. Mexico Brain Tumor Therapeutics, by Tumor Type USD Million (2018-2023)
  • Table 103. Brain Tumor Therapeutics: by Type(USD/Units)
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Brain Tumor Therapeutics: by Type(USD Million)
  • Table 112. Brain Tumor Therapeutics MRI , by Region USD Million (2024-2029)
  • Table 113. Brain Tumor Therapeutics CT Scan , by Region USD Million (2024-2029)
  • Table 114. Brain Tumor Therapeutics Tissue Sampling , by Region USD Million (2024-2029)
  • Table 115. Brain Tumor Therapeutics PET-CT Scan , by Region USD Million (2024-2029)
  • Table 116. Brain Tumor Therapeutics Cerebral Arteriogram , by Region USD Million (2024-2029)
  • Table 117. Brain Tumor Therapeutics Lumbar Puncture , by Region USD Million (2024-2029)
  • Table 118. Brain Tumor Therapeutics Molecular Testing , by Region USD Million (2024-2029)
  • Table 119. Brain Tumor Therapeutics EEG , by Region USD Million (2024-2029)
  • Table 120. Brain Tumor Therapeutics: by Treatment Type(USD Million)
  • Table 121. Brain Tumor Therapeutics Surgery , by Region USD Million (2024-2029)
  • Table 122. Brain Tumor Therapeutics Radiation Therapy , by Region USD Million (2024-2029)
  • Table 123. Brain Tumor Therapeutics Targeted Therapy , by Region USD Million (2024-2029)
  • Table 124. Brain Tumor Therapeutics Chemotherapy , by Region USD Million (2024-2029)
  • Table 125. Brain Tumor Therapeutics Immunotherapy , by Region USD Million (2024-2029)
  • Table 126. Brain Tumor Therapeutics Others , by Region USD Million (2024-2029)
  • Table 127. Brain Tumor Therapeutics: by Tumor Type(USD Million)
  • Table 128. Brain Tumor Therapeutics Primary Brain Tumor , by Region USD Million (2024-2029)
  • Table 129. Brain Tumor Therapeutics Secondary Brain Tumor , by Region USD Million (2024-2029)
  • Table 130. South America Brain Tumor Therapeutics, by Country USD Million (2024-2029)
  • Table 131. South America Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 132. South America Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 133. South America Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 134. Brazil Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 135. Brazil Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 136. Brazil Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 137. Argentina Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 138. Argentina Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 139. Argentina Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 140. Rest of South America Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 141. Rest of South America Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 142. Rest of South America Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 143. Asia Pacific Brain Tumor Therapeutics, by Country USD Million (2024-2029)
  • Table 144. Asia Pacific Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 145. Asia Pacific Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 146. Asia Pacific Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 147. China Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 148. China Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 149. China Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 150. Japan Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 151. Japan Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 152. Japan Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 153. India Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 154. India Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 155. India Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 156. South Korea Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 157. South Korea Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 158. South Korea Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 159. Taiwan Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 160. Taiwan Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 161. Taiwan Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 162. Australia Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 163. Australia Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 164. Australia Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 165. Rest of Asia-Pacific Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 166. Rest of Asia-Pacific Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 167. Rest of Asia-Pacific Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 168. Europe Brain Tumor Therapeutics, by Country USD Million (2024-2029)
  • Table 169. Europe Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 170. Europe Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 171. Europe Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 172. Germany Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 173. Germany Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 174. Germany Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 175. France Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 176. France Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 177. France Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 178. Italy Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 179. Italy Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 180. Italy Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 181. United Kingdom Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 182. United Kingdom Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 183. United Kingdom Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 184. Netherlands Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 185. Netherlands Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 186. Netherlands Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 187. Rest of Europe Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 188. Rest of Europe Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 189. Rest of Europe Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 190. MEA Brain Tumor Therapeutics, by Country USD Million (2024-2029)
  • Table 191. MEA Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 192. MEA Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 193. MEA Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 194. Middle East Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 195. Middle East Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 196. Middle East Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 197. Africa Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 198. Africa Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 199. Africa Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 200. North America Brain Tumor Therapeutics, by Country USD Million (2024-2029)
  • Table 201. North America Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 202. North America Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 203. North America Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 204. United States Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 205. United States Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 206. United States Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 207. Canada Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 208. Canada Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 209. Canada Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 210. Mexico Brain Tumor Therapeutics, by Type USD Million (2024-2029)
  • Table 211. Mexico Brain Tumor Therapeutics, by Treatment Type USD Million (2024-2029)
  • Table 212. Mexico Brain Tumor Therapeutics, by Tumor Type USD Million (2024-2029)
  • Table 213. Brain Tumor Therapeutics: by Type(USD/Units)
  • Table 214. Research Programs/Design for This Report
  • Table 215. Key Data Information from Secondary Sources
  • Table 216. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Brain Tumor Therapeutics: by Type USD Million (2018-2023)
  • Figure 5. Global Brain Tumor Therapeutics: by Treatment Type USD Million (2018-2023)
  • Figure 6. Global Brain Tumor Therapeutics: by Tumor Type USD Million (2018-2023)
  • Figure 7. South America Brain Tumor Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Brain Tumor Therapeutics Share (%), by Country
  • Figure 9. Europe Brain Tumor Therapeutics Share (%), by Country
  • Figure 10. MEA Brain Tumor Therapeutics Share (%), by Country
  • Figure 11. North America Brain Tumor Therapeutics Share (%), by Country
  • Figure 12. Global Brain Tumor Therapeutics: by Type USD/Units (2018-2023)
  • Figure 13. Global Brain Tumor Therapeutics share by Players 2023 (%)
  • Figure 14. Global Brain Tumor Therapeutics share by Players (Top 3) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. NOVARTIS [Switzerland] Revenue, Net Income and Gross profit
  • Figure 17. NOVARTIS [Switzerland] Revenue: by Geography 2023
  • Figure 18. F. HOFFMAN LA-ROCHE LTD. [Switzerland] Revenue, Net Income and Gross profit
  • Figure 19. F. HOFFMAN LA-ROCHE LTD. [Switzerland] Revenue: by Geography 2023
  • Figure 20. MERCK & CO. Inc. [United States] Revenue, Net Income and Gross profit
  • Figure 21. MERCK & CO. Inc. [United States] Revenue: by Geography 2023
  • Figure 22. IMMUNOCELLULAR THERAPEUTICS LTD. [United States] Revenue, Net Income and Gross profit
  • Figure 23. IMMUNOCELLULAR THERAPEUTICS LTD. [United States] Revenue: by Geography 2023
  • Figure 24. NOVOCURE [United States] Revenue, Net Income and Gross profit
  • Figure 25. NOVOCURE [United States] Revenue: by Geography 2023
  • Figure 26. DEL MAR PHARMACEUTICALS INC. [Canada] Revenue, Net Income and Gross profit
  • Figure 27. DEL MAR PHARMACEUTICALS INC. [Canada] Revenue: by Geography 2023
  • Figure 28. MOLECULIN BIOTEC. [United States] Revenue, Net Income and Gross profit
  • Figure 29. MOLECULIN BIOTEC. [United States] Revenue: by Geography 2023
  • Figure 30. Global Brain Tumor Therapeutics: by Type USD Million (2024-2029)
  • Figure 31. Global Brain Tumor Therapeutics: by Treatment Type USD Million (2024-2029)
  • Figure 32. Global Brain Tumor Therapeutics: by Tumor Type USD Million (2024-2029)
  • Figure 33. South America Brain Tumor Therapeutics Share (%), by Country
  • Figure 34. Asia Pacific Brain Tumor Therapeutics Share (%), by Country
  • Figure 35. Europe Brain Tumor Therapeutics Share (%), by Country
  • Figure 36. MEA Brain Tumor Therapeutics Share (%), by Country
  • Figure 37. North America Brain Tumor Therapeutics Share (%), by Country
  • Figure 38. Global Brain Tumor Therapeutics: by Type USD/Units (2024-2029)
List of companies from research coverage that are profiled in the study
  • NOVARTIS [Switzerland]
  • F. HOFFMAN LA-ROCHE LTD. [Switzerland]
  • MERCK & CO. Inc. [United States]
  • IMMUNOCELLULAR THERAPEUTICS LTD. [United States]
  • NOVOCURE [United States]
  • DEL MAR PHARMACEUTICALS INC. [Canada]
  • MOLECULIN BIOTEC. [United States]
Additional players considered in the study are as follows:
Siemens Healthineers [Germany] , Hitachi Healthcare [United States] , Philips Healthcare [Netherlands] , Canon Medical Systems Corporation [Japan] , Shimadzu Corp [Japan]
Select User Access Type

Key Highlights of Report


Jan 2024 200 Pages 96 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Brain Tumor Therapeutics Market Quantitative research analysis
Global Brain Tumor Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as NOVARTIS [Switzerland], F. HOFFMAN LA-ROCHE LTD. [Switzerland], MERCK & CO. Inc. [United States], IMMUNOCELLULAR THERAPEUTICS LTD. [United States], NOVOCURE [United States], DEL MAR PHARMACEUTICALS INC. [Canada] and MOLECULIN BIOTEC. [United States] etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Emerging Applications of Gene Therapy in Regenerative Medicine Technological Advances in Regenerative Medicine (Stem Cell, Tissue Engineering, and Nanotechnology)" is seen as one of major influencing trends for Brain Tumor Therapeutics Market during projected period 2023-2029.
The Brain Tumor Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Brain Tumor Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Retinal Biologics Comprehensive Study by Application (Hospitals, Clinics, Research Organizations, Others), Diagnostic Tests (Amsler grid test, Optical coherence tomography (OCT), Fundus autofluoresce...
$ 3650
Enteric Empty Capsules Comprehensive Study by Type (Gelatin Capsules (Pig Meat Gelatin, Bovine-Derived Gelatin.Bone Meal, and Other Gelatin Sources), Non-Gelatin Capsules (Hydroxypropyl Methylcellulo...
$ 3750
Mouth Ulcer Treatment Drug Comprehensive Study by Route of Administration (Oral, Topical), Drugs Class (Corticosteroid, Analgesic, Antibiotic, Anti-Inflammatory, Others), Distribution Channel (Hospit...
$ 3800
Alopecia Treatment Comprehensive Study by Type (Topical Drugs (Creams, Oils, Gels, Shampoo, Lotions, Foams), Oral Drugs, Injectable Drugs (Platelet-rich Plasma. Injections, Injectable Fillers), Hair ...
$ 3750
Sleep Disorders Comprehensive Study by Type (Mattresses and Pillows, Sleep Laboratories, Medications, Sleep Disorder Devices), Category (Insomnia, Hypersomnia, Sleep apnea, Sleep breathing disorders,...
$ 3750
Throat Lozenges Comprehensive Study by Type (Hard Candy Lozenges, Soft Lozenges, Compressed Lozenges), Application (Pharmacy, Convenience Store, Other), Composition (Pectin Composition, Zinc Gluconat...
$ 3650